© 2018 Miraculo Inc. All Rights Reserved
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuroprotection.
Cannabinoids are chemicals naturally found in the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have illustrated it has anti inflammatory effects when induced on animal cells. People have smoked cannabis for thousands of years and it has said to have an anti inflammatory role in the body. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said it has psychoactive effects. Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow cannabinoids to work in the body. This paper will look at how cannabinoids can be used for protecting the brain against diseases such as multiple sclerosis (MS).
THC and CBD can be useful treatment for MS-induced neuropathic pain
Central neuropathic pain (CNP) thrives in many people with multiple sclerosis. This paper reports the first study of the efficacy of the endocannabinoid system modulator THC/CBD oromucosal spray (sativex) to reduce symptoms of CNP. Patients who haven’t gained proper analgesia from conventional medication were treated with THC/CBD spray for 14 weeks to see the effectiveness of the medication in MS-induced neuropathic pain. This was followed by an 18 week withdrawal study. A total of 339 patients were randomized and 58 were selected for the withdrawal study.The results of this study were conflicting in that there were a large amount of responders to THC/CBD spray treatment during the initial 14 week. In contrast, there was a marked effect in the withdrawl part of the study, with an increased time to treatment failure in the THC/CBD spray group. These findings suggest that further studies are required to explore the full potential of THC/ CBD spray in patients with MS.
Cannabinoids can have a therapeutic effect
In conclusion, it was discovered that in this treatment-resistant population, the THC/CBD spray displayed a high response rate at week 10 but not at the week 14 primary endpoint in the first part of the study. It is concluded that this study has given further results useful for determining the effectiveness of THC/CBD spray in the treatment of CNP due to MS. The results support published proposals in the past that this kind of study design may be of specific value in finding clinically relevant responses in this patient population, and suggest that future research may be good from the administration of a balanced dosing schedule between the different arms of the experiment.MS0510_Ratcliffe_JofNeurol_20122copy